A Study of Effects of Selpercatinib (LY3527723) on Midazolam in Healthy Participants
Status:
Completed
Trial end date:
2018-09-18
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess the effect of selpercatinib on how fast midazolam
gets into the blood stream and how long it takes the body to remove it when administered in
healthy participants. Information about safety and tolerability will be collected. The study
will last up to about 6 weeks, inclusive of screening period.